Log in
Enquire now
Kurma Partners

Kurma Partners

Kurma Partners invests in healthcare and biotechnology companies in Europe.

OverviewStructured DataIssuesContributors

Contents

kurmapartners.com/en
kurmapartners.com
Is a
Investor
Investor
Venture capital firm
Venture capital firm
Organization
Organization
Company
Company

Company attributes

Industry
Biology
Biology
Biotechnology
Biotechnology
Healthcare
Healthcare
Neuroscience
Neuroscience
Technology
Technology
Neurotechnology
Neurotechnology
Life science
Life science
Location
Paris
Paris
0
Münchenbernsdorf
Münchenbernsdorf
0
B2X
B2B
B2B
Founder
‌
Thierry Laugel
0
Pitchbook URL
pitchbook.com/profiles.../42348-43
Number of Employees (Ranges)
11 – 500
Email Address
contact@kurmapartners.com
Phone Number
+331848608610
+4989236859300
Full Address
24 rue royale, Paris, Paris 750080
Maximilianstraße 29 80539 Munchen Germany0
Founded Date
2009
0
Glassdoor ID
1132416
Key People
‌
Jean-François Rivassou
0
‌
Daniel Parera
0
‌
Philippe Peltier
0
‌
Sylvain Cascarino
0
‌
Amine Marouf
0
‌
Hadrien Bouchez
0
‌
Thierry Laugel
0
‌
Benjamin Belot
0
...
Country
France
France
0
Germany
Germany
0

Venture Capital Firm attributes

Invested in
Sensome (Formerly Instent)
Sensome (Formerly Instent)
0
Pharvaris
Pharvaris
0
Amolyt Pharma
Amolyt Pharma
0
‌
Asarina Pharma
0
0
Charles
Charles
0
Omnidoc
Omnidoc
0
Altamira Therapeutics Ltd.
Altamira Therapeutics Ltd.
0
...

Other attributes

Company Operating Status
Active

Founded in 2009, Kurma Partners is a venture capital firm based in Paris, France. Kurma Partners is a key European player in the financing of innovation in healthcare and biotechnology, from pre-seed to growth capital.

Kurma Partners manages the Kurma Biofund I, II and III funds and the Kurma Diagnostics fund and is involved in the financing of therapeutic and medical innovations in Europe, particularly through their links with medical institutes, research institutes and hospitals.

Investment

Kurma Partners' investments include FeetMe, Tacalyx, Ermium Therapeutics, Pharvaris, AM Pharma, DNA Script and Asarina Pharma.

Their exited investments include Minoryx Therapeutics, STAT-Dx, Alizé Pharma, Orphazyme, Asarina Pharma and Safe Orthopaedics.

Funds

Kurma Partners has raised a total of €291 million across 4 funds, their latest being Kurma Biofund III. This fund was announced on December 17, 2018 and raised a total of €150 million. They announced their Kurma Diagnostics Fund on May 26, 2015 with a raised total of €35 million. Their Kurma Biofund II on June 20, 2013 with a raised total of €55 million. And they announced their Kurma Biofund I on January 1, 2010 with a raised total of €51 million.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Associated Investment Funds

Accelerator Batches

Patents

Funding Rounds Participated In

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Kurma Partners

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.